Developed cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.
ViaCyte
Life Sciences, Venture Debt
Developed cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.